OptiNose — Q2 2019 Earnings Presentation
18 slides from OptiNose's earnings presentation, Aug 12, 2019
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 12, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Q2 2019 Key Highlights
Q2 2019 Key Highlights XHANCE Prescription Volume • 50%+ quarter-over-quarter growth (third consecutive quarter) • Continued growth for both NRx and refill rate in Q2 2019 Average Net Revenue per Prescription • Avg. Net Revenue per TRx of $197 in Q2 2019 and $189 for H1 2019 (in line with full year
Slide 4: XHANCE Launch Update
XHANCE Launch Update optinose_ ————
Slide 5: Commercial Strategy is Successfully Growing XHANCE
Commercial Strategy is Successfully Growing XHANCE And Additional Accelerators Support this Strategy Differentiate Drive New Patient Access and XHANCE on Efficacy Starts Affordability � Newly available post- � 25% Increase in � New payer contracts hoc subgroup Sales Territories including access to a
Slide 6: Patients with symptoms despite nasal steroids improved significantly when switched to XHANCE
Patients with moderate-to-severe symptoms despite using conventional nasal steroids† improved significantly when switched to XHANCE Post-Hoc Analysis of NAVIGATE I/II Pooled Data (n=482): At study entry, a large subgroup (30%) of the patients in the pooled NAVIGATE I/II trials reported using a conve
Slide 7: DTC Approach: Pilot. Learn. Expand.
DTC Approach: Pilot. Learn. Expand. We invite you to view the XHANCE Television Ad starting the week of August 19th on the XHANCE Facebook page, and on YouTube 7
Slide 8: XHANCE Prescription Volume Grew 51% in Q2 versus Q1 2019
XHANCE Prescription Volume Grew 51% in Q2 versus Q1 2019 and 17% in July versus June 2019 Strong growth in both new prescriptions and refills drove XHANCE quarterly prescription growth of 51% in Q2 2019. XHANCE TRx +51% XHANCE TRx 35,000 33,949 20,000 +59% +17% vs June 2019 30,000 +50% 15,000 13,770
Slide 9: XHANCE Share of INS Prescriptions Within Target Physician Audience is Growing
XHANCE Share of INS Prescriptions Within the Target Physician Audience is Growing and the Remaining Opportunity is Large Market share within target physician audience has increased consistently in 2019 XHANCE Share of INS TRx Within Target Physician Audience 3.0% 2.9% 2.6% 2.5% 2.3% 2.0% 2.0% 1.7% 1
Slide 10: Q2 2019 Financial Update
Q2 2019 Financial Update optinose_ ————
Slide 11: Financial Review – Second Quarter 2019
Financial Review – Second Quarter 2019 Q2 2019 XHANCE Net Revenues and Average Net Revenue per TRx ($M ) XHANCE Net Revenue Average Net Revenue per TRx Increased 68% in Q2 versus Q1 $6.7 � Average XHANCE net revenue of $197 per TRx in Q2 2019 – 11% Increase compared to $4.0 $177 in Q1 2019 $3.0 � Av
Slide 12: 2019 Financial Guidance
2019 Financial Guidance � Full Year XHANCE net revenue expected to be in the range of $29 - $34 million � Continue to expect Full Year 2019 average net revenue per prescription of XHANCE to be in the range of $185 - $205 � Full Year 2019 Operating Expenses (GAAP) expected to be in the range of $128
Slide 13: Pipeline Update
Pipeline Update optinose_ ————
Slide 14: XHANCE Chronic Sinusitis Indication (sNDA)
XHANCE Chronic Sinusitis Indication (sNDA) The Chronic Sinusitis development program includes two Phase 3b clinical trials that are 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter studies • First patient enrolled in Q4 2018 Study 3205 • Estimated enrollment: 378 pat
Slide 15: Closing Remarks
Closing Remarks optinose_ ————
Slide 16: Q2 2019 Key Highlights
Q2 2019 Key Highlights XHANCE Prescription Volume • 50%+ quarter-over-quarter growth (third consecutive quarter) • Continued growth for both NRx and refill rate in Q2 2019 Average Net Revenue per Prescription • Avg. Net Revenue per TRx of $197 in Q2 2019 and $189 for H1 2019 (in line with full year
Slide 17: Investor Relations
Investor Relations – NASDAQ: OPTN At 30 June 2019: Analyst Coverage1 – $144 million in cash – Long-term debt: $75 million BMO: Gary Nachman – 41.4 million common shares o/s – 9.9 million options & warrants o/s Jefferies: David Steinberg Cantor Fitzgerald: Brandon Folkes Optinose Investor Contact Jon
Slide 18: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 12, 2019